atopic dermatitis
Conditions
Interventions
Test group:therapeutic agents: abrocitinib or upadacitinib
Sponsors
Guangzhou Dermatology Hospital
Eligibility
Sex/Gender
All
Age
No minimum to 11 Years
Inclusion criteria
Inclusion criteria: The patients enrolled were below 12 years of age; Patients had a definite diagnosis of AD, which was based on the Williams criteria; At screening, patients' AD severity was consistent with EASI =16, IGA =3, and PP-NRS =4.
Exclusion criteria
Exclusion criteria: Serious infections; Persons who are receiving or preparing to receive live or live attenuated vaccines; Persons with immunodeficiency; Persons who are allergic to abrocitinib, upadacitinib and any of the drug components contained therein; Presence of other systemic diseases or active skin diseases (e.g., psoriasis or lupus erythematosus, etc.) that may affect AD or study results; Persons with markedly abnormal cardiac, hepatic, or renal function results that would interfere with the administration of the drug; Subjects who, in the opinion of the investigator, are uncooperative or unable to comply with the study procedures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cytokine;clinical efficacy score;routine blood test;total IgE; | — |
Countries
China
Contacts
Public ContactHui Ye
Guangzhou Dermatology Hospital
Outcome results
None listed